SAFETY AND EFFICACY OF STATIN MANAGEMENT DURING GLECAPREVIR/PIBRENTASVIR TREATMENT FOR CHRONIC HEPATITIS C

التفاصيل البيبلوغرافية
العنوان: SAFETY AND EFFICACY OF STATIN MANAGEMENT DURING GLECAPREVIR/PIBRENTASVIR TREATMENT FOR CHRONIC HEPATITIS C
المؤلفون: Joseph Gathe, Peter Jones, Ariel Porcalla, Federico J. Mensa, Lisa Barcomb, Paul Kwo, Yao Yu, Peter Toth, Douglas E. Dylla
المصدر: Journal of the American College of Cardiology. 71:A1763
بيانات النشر: Elsevier BV, 2018.
سنة النشر: 2018
مصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, Statin, business.industry, medicine.drug_class, 030106 microbiology, nutritional and metabolic diseases, Glecaprevir, Pibrentasvir, Virus, 03 medical and health sciences, 0302 clinical medicine, Chronic hepatitis, Concomitant, Internal medicine, Medicine, lipids (amino acids, peptides, and proteins), 030211 gastroenterology & hepatology, Rosuvastatin, Cardiology and Cardiovascular Medicine, business, Pravastatin, medicine.drug
الوصف: Some statins are not recommended for concomitant use with glecaprevir/pibrentasvir (G/P) treatment for chronic hepatitis C virus infection. We analyzed the impact of switching to rosuvastatin or pravastatin compared to maintaining or interrupting current statin use. Safety and efficacy data from
تدمد: 0735-1097
DOI: 10.1016/s0735-1097(18)32304-0
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::e4571d300bf101189df8e4a049b314b7
https://doi.org/10.1016/s0735-1097(18)32304-0
Rights: CLOSED
رقم الانضمام: edsair.doi...........e4571d300bf101189df8e4a049b314b7
قاعدة البيانات: OpenAIRE
الوصف
تدمد:07351097
DOI:10.1016/s0735-1097(18)32304-0